News | December 07, 2024
Briefs: Venus Remedies and GPT Healthcare
Venus Remedies secures marketing authorization in Philippines
Venus Remedies secures marketing authorization in Philippines
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
Reaffirms Lupin’s commitment to sustainable resource management
For people with relapsed or refractory diffuse large B-cell lymphoma
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
Granules has undertaken a proactive, voluntary and comprehensive remediation plan to address the six form 483 observations raised by the USFDA
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
Subscribe To Our Newsletter & Stay Updated
